DCGI approves anti-covid drug developed by DRDO for emergency use
Published By : Prameya News Bureau | May 08, 2021 IST
Share
New Delhi, May 8: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19. Pursuing Prime Minister Narendra Modi’s call for preparedness against the pandemic, DRDO took the initiative of developing anti-COVID therapeutic application of 2-DG. In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020. The DRDO, along with its industry partner DRL, Hyderabad, started the clinical trials to test the safety and efficacy of the drug in COVID-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery. Phase IIa was conducted in six hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC. Based on successful results, DCGI further permitted the Phase-III clinical trials in November 2020. The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of phase-III clinical trial was presented to DCGI. In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC, indicating an early relief from Oxygen therapy/dependence. The similar trend was observed in patients aged more than 65 years. On May 01, 2021, DCGI granted permission for Emergency Use of this drug as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country. The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique. In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients.
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
Lok Sabha polls: PM Modi links 'dholak', Mohd Shami with Amroha's pride
Lok Sabha polls: 15 pc voter turnout recorded in MP's six LS seats in first two hours
Lok Sabha polls: Rajasthan CM Bhajanlal Sharma casts vote
Lok Sabha polls: Nitin Gadkari casts vote in Nagpur, says BJP will cross 400 seats
Lok Sabha polls 2024: Will register historic win in TN, says state BJP chief K. Annamalai
LS polls 2024: PM Modi to campaign in UP, MP and Maharashtra today
Vice-Admiral Dinesh Tripathi appointed as new Navy Chief
Lok Sabha Elections 2024: Tamil Superstar Ajith Kumar sets early example by voting
Vice-Admiral Dinesh Kumar Tripathi appointed as next Chief of Naval Staff
Polling begins for Tripura West Lok Sabha Seat and Ramnagar Assembly By-Polls
Nagaland LS Election 2024: Voting commences amidst security measures
Virat Kohli's statue installed at Jaipur Wax Museum on World Heritage Day
Punjab electoral officer to go Live for election-related queries
Jilted lover stabs corporator's daughter to death in Karnataka college campus
Nestle baby food sugar study causes concern in India, Nestle India's shares fall
'Yamraj' files nomination as Independent for Maharashtra's Madha LS seat
ED reveals Kejriwal's high glycaemic index diet plan, AAP alleges political vendetta
Suprme Court reserves verdict on pleas seeking mandatory EVM-VVPAT tally
LS poll: BJP nominates Narayan Rane from Ratnagiri Sindhudurg
ED attaches Shilpa Shetty and Raj Kundra's assets worth Rs 98 Cr